Trial Profile
Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1-negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy. (EMERALD study) (WJOG10317L)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2022
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Atezolizumab; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms EMERALD study; RAM+DOC vs Atezo
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 01 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2019 Status changed from not yet recruiting to recruiting.